SPP 676

Drug Profile

SPP 676

Alternative Names: SPP676

Latest Information Update: 22 Jul 2010

Price : $50

At a glance

  • Originator Roche
  • Developer Speedel Experimenta
  • Class Amides; Antihypertensives; Fumarates
  • Mechanism of Action Renin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported End-organ damage; Hypertension

Most Recent Events

  • 09 Jul 2008 Speedel has been acquired by Novartis
  • 17 Apr 2008 SPP 676 is still in phase I trials for Hypertension in Switzerland
  • 10 Oct 2007 Phase-I clinical trials in Hypertension in Switzerland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top